Regulatory press release29.01.2024, 11.26Completion of the combination between Novozymes and Chr. Hansen
Regulatory press release26.01.2024, 12.09All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
Press release20.12.2023, 15.02Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
Regulatory press release19.12.2023, 11.54Major shareholder announcement from Burlington Loan Management DAC
Press release12.12.2023, 17.11Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
Regulatory press release20.11.2023, 08.03Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
Regulatory press release10.10.2023, 08.08Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
Regulatory press release27.09.2023, 09.23Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP
Regulatory press release04.09.2023, 11.48Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
Regulatory press release30.03.2023, 18.07Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
Regulatory press release30.03.2023, 17.57Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S
Regulatory press release30.03.2023, 13.11Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
Regulatory press release28.03.2023, 12.07Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
Regulatory press release08.03.2023, 08.00Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company